DNA Script, a Paris, France-based maker of de novo synthetic nucleic acids using an enzymatic technology, raised $38.5M in Series B funding.
The round was led by LSP, with participation from Bpifrance, through its Large Venture fund and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners.
The company intends to use the funds to accelerate the development of its first products based on its enzymatic technology for de novo synthesis of nucleic acids.
Founded in 2014 by Thomas Ybert, CEO, DNA Script leverages innovative technology to provide rapid, high-quality production of important genomic experimental precursors, such as oligonucleotides. The technology features a novel biochemical process for nucleic acids synthesis based on the use of highly efficient enzymes, thus enabling enhanced performance while minimizing the use of harsh chemicals.
The product portfolio based on DNA Script’s proprietary enzymatic synthesis platform will enable molecular biology researchers to accelerate their experiments — with the goal of moving from design to results within a day for a broad range of applications. The technology has the potential to accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage.
The company is prioritizing the recruitment of top talent in the U.S. for its product development and commercialization teams in preparation for product launch, as well as on expanding its Paris-based research team.